Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Healthy
Interventions: crizotinib, ketoconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Obesity, Metabolic Disease, Cold Exposure
Interventions: Cold Vest Exposure Period, Rewarming Exposure Period, Fasting; Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 99
States / cities: Little Rock, Arkansas • Concord, California • Escondido, California + 80 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Shape II CPET; Device
Lead sponsor: Shape Medical Systems, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 6
States / cities: Torrance, California • Denver, Colorado • Jacksonville, Florida + 3 more

Conditions: Healthy, Kidney Stone, Obesity
Interventions: Low-oxalate controlled diet, Primed, continuous intravenous infusion of 13C2-oxalate; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Transtibial Amputation, Peripheral Artery Disease, Diabetes Mellitus
Interventions: Error-augmentation gait training, Error-correction gait training, Supervised walking; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Richmond, Virginia

Conditions: Cystic Fibrosis
Interventions: 129Xe; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 8 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Charlottesville, Virginia

Conditions: Renal Impairment
Interventions: S-217622; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Saint Paul, Minnesota

Conditions: Relapsed or Refractory Lymphoma
Interventions: HMPL-523, Rabeprazole; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: To Determine the Bioavailability of Tranylcypromine
Interventions: Tranylcypromine, Parnate; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Diabetes Mellitus
Interventions: Diabetes Outcome; Diagnostic Test
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 80 Years
Enrollment: 34,121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: LY3023414 Reference Fasted, LY3023414 Test Fasted, LY3023414 Test Fed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: University of North Carolina; Other
Eligibility: 20 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: LY3410738, Esomeprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Panic Disorder, Major Depressive Disorder
Interventions: Active Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions: Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177); Biological · Other · Drug
Lead sponsor: Beat AML, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Hepatitis C, Chronic
Interventions: GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 54
States / cities: Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more

Conditions: Medullary Thyroid Cancer, Colon Cancer
Interventions: Tumor Genomic Analysis; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hematopoietic Stem Cell Transplant
Interventions: 12-16 hour nutrition; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Months and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions: Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Little Rock, Arkansas • Concord, California • Escondido, California + 35 more

Conditions: Diabetes, Type I
Interventions: Technosphere Insulin, Active comparator; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 589 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Mobile, Alabama • Chandler, Arizona • Chula Vista, California + 48 more

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obsessive-Compulsive Disorder
Interventions: Ketamine, Naltrexone Pill, Placebo pill; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 2 Diabetes Mellitus
Interventions: LY3209590, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Concord, California + 33 more

Search by objective public record fields.

Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers

Thermogenic Silencer Regulatory Factors in Humans

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Assessing the Utility of Submaximal CPET in Treatment Management of PAH

Assessment of Endogenous Oxalate Synthesis

Optimizing Gait Rehabilitation for Veterans With Non-traumatic Lower Limb Amputation

BEGIN Novel ImagiNG Biomarkers

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

HMPL-523 Food Effect and Proton Pump Inhibitor Study

Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions

Walnut Consumption and Diabetes Risk

A Study of LY3023414 Formulations and the Effect of Food

Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer

Time Restricted Nutrition in Pediatric Stem Cell Transplant Recipients

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)

A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus